Disposition of 90000 shares by Gary Pace of Pacira Pharmaceuticals at 30.6 subject to Rule 16b-3
| PCRX Stock | USD 22.36 0.30 1.36% |
Slightly above 54% of Pacira BioSciences,'s investors are presently thinking to get in. The analysis of overall sentiment of trading Pacira BioSciences, stock suggests that some investors are interested at this time. Pacira BioSciences,'s investing sentiment can be driven by a variety of factors including economic data, Pacira BioSciences,'s earnings reports, geopolitical events, and overall market trends.
Pacira |
Filed transaction by Pacira Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Pacira BioSciences, Fundamental Analysis
We analyze Pacira BioSciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Pacira BioSciences, is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Pacira BioSciences, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pacira BioSciences, stock to make a market-neutral strategy. Peer analysis of Pacira BioSciences, could also be used in its relative valuation, which is a method of valuing Pacira BioSciences, by comparing valuation metrics with similar companies.
Peers
Pacira BioSciences, Related Equities
| HCM | HUTCHMED DRC | 6.61 | ||||
| IXHL | Incannex Healthcare | 4.32 | ||||
| ANIP | ANI Pharmaceuticals | 1.67 | ||||
| RDY | Dr Reddys | 0.47 | ||||
| PBH | Prestige Brand | 0.38 | ||||
| ITCI | Intracellular | 0.05 | ||||
| COLL | Collegium Pharmaceutical | 0.33 | ||||
| PAHC | Phibro Animal | 0.53 | ||||
| ALKS | Alkermes Plc | 0.94 |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.